Autism in adults
Exam Tips
- In OSCEs, state clearly that there is no single biomarker test for ASD; diagnosis is clinical and multidisciplinary with developmental history.
- Use the high-yield triad: social-communication differences, restricted/repetitive patterns, and functional impact across settings.
- Mention common comorbidity proactively (anxiety/depression/ADHD/OCD) and that comorbidity often drives help-seeking.
- Key prescribing point: do not prescribe medication for core ASD features; prescribe only for defined comorbidities or severe risk behaviour with monitoring.
- Safety point for viva: in-utero valproate exposure is a recognised risk factor for neurodevelopmental disorders; avoid valproate in people who can become pregnant unless strict pregnancy prevention requirements are met.
- If asked about epidemiology, quote UK adult prevalence around 1.1% and note likely underdiagnosis in older adults, females, and gender-diverse people due to camouflaging.
- See Figure from your psychiatry revision text showing adult autism diagnostic pathway (screen -> specialist assessment -> support planning; page varies by edition).
Definition
Autism spectrum disorder (ASD) in adults is a lifelong neurodevelopmental condition characterised by persistent differences in social communication/interaction and restricted, repetitive patterns of behaviour, interests, or routines. Adult presentation is heterogeneous: some people live independently with subtle but functionally significant social and sensory difficulties, while others have substantial support needs, especially when coexisting intellectual disability, language impairment, or mental illness is present.
Pathophysiology
ASD reflects atypical brain development rather than a degenerative disease process. Current models describe strong genetic loading (including synaptic and neurodevelopmental pathway variants) interacting with prenatal/perinatal environmental exposures, leading to altered cortical connectivity, sensory processing, social cognition, executive function, and emotional regulation. Neurobiologically, differences are often framed as network-level changes ("social brain" and salience/executive circuits), with variable excitatory-inhibitory signalling and atypical developmental pruning; these mechanisms help explain sensory hypersensitivity, insistence on sameness, and difficulty adapting to social ambiguity. See Figure from your neurodevelopment chapter illustrating social-communication networks and frontostriatal rigidity pathways (page varies by textbook edition).
Risk Factors
- Male sex at diagnosis (observed ratio commonly around 3:1 to 5:1, while females may be under-recognised due to camouflaging)
- Family history of ASD (higher sibling recurrence risk)
- Monozygotic twin concordance markedly higher than dizygotic twins
- Associated genetic syndromes (for example Fragile X syndrome, Angelman syndrome, Rett syndrome, tuberous sclerosis)
- Chromosomal conditions (for example Down syndrome, Turner syndrome)
- Advanced parental age
- In-utero sodium valproate exposure
- Prematurity (<35 weeks), very low birth weight (<1500 g), perinatal hypoxia
- Maternal factors (for example obesity, pre-eclampsia, vitamin D deficiency, some peri-/postnatal infections)
- Parental severe mental illness
- Coexisting neurodevelopmental disorders (for example intellectual disability, ADHD)
Clinical Features
Symptoms
- Lifelong difficulty with reciprocal conversation, reading social cues, and understanding implied meaning
- Social anxiety, exhaustion after social interaction, and preference for predictable routines
- Distress with change, uncertainty, or disrupted routines
- Restricted or highly focused interests (often intense and detail-driven)
- Sensory hyper- or hyposensitivity (noise, light, touch, textures, smells)
- Functional impairment in education, employment, relationships, or independent living
- Emotional dysregulation, shutdowns/meltdowns, or marked anxiety in overstimulating settings
Signs
- Atypical eye contact, prosody, gesture use, or social timing
- Monologue style, literal interpretation of language, difficulty with turn-taking
- Observed rigidity, repetitive behaviours, and strong preference for sameness
- Narrow but deep interest profile that dominates discussion/activities
- Apparent social naivety or vulnerability to exploitation
- Coexisting psychiatric or neurodevelopmental signs (for example depression, ADHD traits, OCD features, tic disorder)
Investigations
Management
Lifestyle Modifications
- Psychoeducation for patient and (with consent) family/carers, explaining strengths, support needs, and legal rights
- Structured support plan: predictable routines, sensory adaptations, clear communication, and reasonable adjustments at work/education
- Access to autism-informed psychological and social interventions (skills for daily living, relationships, anxiety management, employment support)
- Treat physical health proactively (annual review, sleep, diet, exercise, bowel and epilepsy screening where relevant)
- Crisis/safety planning for self-harm, suicidality, exploitation, or severe functional deterioration
Pharmacological Treatment
Core ASD symptoms
- No medication is recommended to treat core social-communication differences or restricted/repetitive behaviours in adults
Do not start psychotropic medication solely for core autism features; prioritise psychosocial and environmental intervention.
Depression/anxiety/OCD comorbidity (if indicated)
- Sertraline 50 mg once daily initially, increase in steps to a usual maximum of 200 mg/day
- Fluoxetine 20 mg once daily initially, titrate according to response (commonly up to 60 mg/day)
Start low, titrate slowly, and monitor activation, GI adverse effects, sleep change, and suicidality (especially in younger adults). Check interactions (for example serotonergic toxicity risk with other agents).
Severe irritability/aggression/challenging behaviour (specialist, usually off-label in autistic adults)
- Risperidone 0.5 mg/day initial dose (or 0.25 mg twice daily), titrate cautiously to the lowest effective dose; many adults respond within 1-2 mg/day
Use only after clear formulation and failure of psychosocial/environmental strategies, and when risk is significant. Monitor weight, glucose/HbA1c, lipids, prolactin, EPS, sedation, and QT risk; review regularly and attempt dose reduction/withdrawal when possible.
Comorbid ADHD (specialist assessment required)
- Methylphenidate MR 18 mg once each morning initially, titrated weekly to response (adult maximum depends on product, commonly up to 54-72 mg/day)
- Lisdexamfetamine 30 mg once each morning initially, increase by 20 mg at roughly weekly intervals (maximum 70 mg/day)
Before stimulants: baseline pulse, blood pressure, weight/BMI, cardiovascular history, and risk assessment. Contraindications/cautions include symptomatic cardiovascular disease, uncontrolled hypertension, and misuse risk.
Sleep disturbance (selected cases)
- Melatonin modified-release 2 mg 1-2 hours before bedtime (off-label in many adults under 55 years)
Use after sleep-hygiene and behavioural measures; review benefit and next-day sedation. Check interacting sedatives and driving safety.
Complications
- Social isolation, loneliness, and relationship breakdown
- Unemployment or underemployment; workplace conflict and reduced financial independence
- Higher rates of anxiety, depression, OCD, ADHD, eating disorders, and sleep disorders
- Increased risk of self-harm and suicide
- Diagnostic overshadowing and delayed treatment of physical illness
- Reduced quality of life and higher risk of premature mortality
- Greater vulnerability to exploitation, abuse, and safeguarding concerns
Prognosis
ASD is lifelong, but functional outcomes vary widely and can improve with timely diagnosis, tailored support, and treatment of comorbidity. Better prognosis is associated with stronger language/cognitive function and absence of significant intellectual disability, while psychiatric comorbidity and neurological disease worsen outcomes. Many adults remain undiagnosed for years; this delay is linked to avoidable distress, poorer social/occupational outcomes, and increased health risk.
Sources & References
🏥BMJ Best Practice(10)
✅NICE Guidelines(1)
- Autism in adults[overview]
📖Textbook References(20)
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1290)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1321)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 637)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 637)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1076)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1076)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1290)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 384)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1321)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 906)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1322)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 593)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 383, 384)[context]
- Guyton and Hall Textbook of Medical Physiology (John E. Hall, Michael E. Hall) (Z-Library).pdf(pp. 888)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 878)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 713, 714)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 712, 713)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 714)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 595)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 712)[context]